Technology
Mesa Laboratories, Inc.(MLAB)
Live Price
Offline$105.48
-1.74% today
1Y Change
-3.25%
Window
Jun 26, 2025 โ Jun 22, 2026
- Market Cap
- $570.00M
- Revenue Growth
- +11.5%
- EPS Growth
- +99.2%
- Dividend Yield
- 0.6%
Coverage: 247 bars ยท Jun 26, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mesa Laboratories, Inc. (MLAB) is a Technology stock with a market cap of $570.00M and listed on NASDAQ. The stock last traded around $105.48 and down 3.2% across the available one-year price window (Jun 26, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +11.5%, EPS growth of +99.2%, a dividend yield of 0.6%. What stands out right now is revenue +11.5%, EPS +99.2%, free cash flow +1.8% with operating margin 7.0% and ROIC 1.2%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 153.1 and price/sales 2.3. Stock Foundry combines MLAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+11.5% vs +11.9% peer median
Operating Margin
Below sector median
+7.0% vs +22.0% peer median
P/E
Above sector median
153.1 vs 18.5 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.5% and EPS at +99.2%, with operating margin around 7.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | +13.5% | +15.0% | โ |
2026 Feb 3, 2026 | +119.3% | +4.6% | +5.0% | +6.1% |
2025 Nov 6, 2025 | +12.8% | +1.5% | +1.3% | +3.7% |
Benchmark Edge
MLAB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MLAB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MLAB Max Drawdown
-44.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MLAB and SPY.
Company Overview
Mesa Laboratories, Inc.
NASDAQ Global Select
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
- Leadership
- Siddhartha Chandrakant Kadia
- IPO Date
- Feb 29, 1984
- Employees
- 736
- Street Address
- 12100 West Sixth Avenue
- Mailing
- Lakewood, CO, 80228
- Region
- Lakewood, CO, US
- Reporting Currency
- USD
- Investor Line
- 303 987 8000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 153.1
- EV/EBITDA
- 14.6
- Price/Sales
- 2.3
- Price/Book
- 3.1
Growth
- Revenue
- +11.5%
- EPS
- +99.2%
- Free Cash Flow
- +1.8%
Profitability
- Gross Margin
- 60.6%
- Operating Margin
- 7.0%
- Net Margin
- 1.5%
- ROE
- 2.1%
- ROIC
- 1.2%
Balance Sheet
- Debt/Equity
- 0.55
- Current Ratio
- 1.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.